{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010393","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.481989+00:00","generated_at":"2026-05-17T20:15:16.826055+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bio-Techne Q4 GAAP EPS -$0.11, adjusted EPS $0.53; organic revenue +3%; announces Exosome divestiture","bullets":["GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.","Q4 organic revenue up 3% (reported 4%) to $317.0M; full year organic +5% to $1.2B.","Protein Sciences segment organic growth 4% (reported 6%) in Q4.","Announced divestiture of Exosome Diagnostics business including ExoDx Prostate test.","Board declared $0.08/share quarterly dividend, payable Aug 29, record Aug 18."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010393","json":"https://secwatch.observer/filing/0001558370-25-010393.json","markdown":"https://secwatch.observer/filing/0001558370-25-010393.md","text":"https://secwatch.observer/filing/0001558370-25-010393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837025010393/0001558370-25-010393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837025010393/tech-20250806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:15:16.826055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}